Very late relapse in an HCV genotype 3-infected patient treated with direct-acting antivirals (DAA)

2019 ◽  
Vol 75 (1) ◽  
pp. 252-253 ◽  
Author(s):  
Cinzia Caudai ◽  
Chiara Papalini ◽  
Daniela Francisci ◽  
Franco Baldelli ◽  
Maurizio Zazzi
Keyword(s):  
Infected Patient ◽  
Late Relapse ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotype 3 ◽  
Direct Acting

scholarly journals Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients

2021 ◽  
Vol 15 (10) ◽  
pp. 1489-1496
Author(s):  
Sonia Younas ◽  
Hamid Mukhtar ◽  
Umar Farooq Gohar ◽  
Abdullah Alsrhani ◽  
Badr Alzahrani ◽  
...  
Keyword(s):  
Side Effects ◽  
Molecular Techniques ◽  
Baseline Viral Load ◽  
Hcv Rna ◽  
Efficacy Rate ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotype 3 ◽  
Direct Acting

Introduction: The conventional interferon therapy of hepatitis C virus has been substituted substantially with sofosbuvir and daclatasvir due to constraints in efficacy and tolerability. This study aimed diagnostically to monitor the effectiveness and side effects of direct-acting antivirals in the management of HCV infections. Methodology: This prospective study was conducted on HCV-infected patients treated with sofosbuvir and daclatasvir. Different serological, biochemical, hematological, and molecular techniques were used for the assessment of patients. Only treatment-naive patients aged ≥ 18 to 75 years received 12 weeks of treatment. The primary endpoint was a sustained virologic response with undetectable HCV RNA in the patients’ serum at the end of the treatment. Results: We identified 229 cases of confirmed HCV infections by PCR, 94.3% of which had genotype 3. The study population comprised 66% females and 34% males with a median age of 42.2 ± 10.6 SD. Ninety-three percent of the patients accomplished SVR at week 12. The combined therapy of SOF/DAC achieved the highest efficacy rate (92.6%) among the different HCV genotype 3 patients. A statistically significant relationship was observed between low baseline viral load (p < 0.001; 95% CI = 1.2-3.1) and HCV genotype 3 with minor side effects, including lethargy, headache, nausea, insomnia, diarrhea, and fever. Conclusions: HCV-infected patients can be treated well with an interferon-free SOF/DAC regimen, tolerated with generally mild adverse effects with a higher SVR.

Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done

2018 ◽  
Vol 17 (5) ◽  
pp. 0-10
Author(s):  
Susana Llerena ◽  
Joaquín Cabezas ◽  
Antonio Cuadrado ◽  
José Manuel Olmos ◽  
Marta González ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Case Reports ◽  
Rescue Therapy ◽  
Virologic Response ◽  
New Combination ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Hcv Genotype 3 ◽  
Almost All ◽  
Direct Acting

Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge. Use a novel retreatment option for patients with a difficult approach. We present three case reports of retreatment with a new combination of Direct-acting antivirals (DAAs), Sofosbuvir, Elbasvir/ Grazoprevir in patients with GT3 with a previous failure with Sofosbuvir/Ledipasvir. All the cases achieved sustained virologic response (SVR) at week +12 without adverse effects. In our experience, this combo may represent an effective and safe option for these patients.

scholarly journals Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α2a Monotherapy

2011 ◽  
Vol 56 (11) ◽  
pp. 3296-3304 ◽  
Author(s):  
Ahmad Amanzada ◽  
Armin Goralczyk ◽  
Federico Moriconi ◽  
Martina Blaschke ◽  
Inga-Marie Schaefer ◽  
...  
Keyword(s):  
Virological Response ◽  
Young Age ◽  
Rapid Virological Response ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotype 3
Sign in / Sign up

Export Citation Format

Share Document